中国经内镜消化系统常见恶性肿瘤组织取样及类器官培养专家共识(2024,成都)

Chinese expert consensus on endoscopic biopsy and organoid culture techniques for gastrointestinal cancers(2024,Chengdu)

消化系统恶性肿瘤是全球主要的癌症病种,其发病率和死亡率均居前列。部分进展期肿瘤需要接受化学治疗、放射治疗、靶向药物治疗或者免疫治疗。肿瘤对治疗的敏感性是决定患者临床结局的关键因素。肿瘤类器官可较好保留原始肿瘤的遗传学特征与生物学行为,可用于评价治疗敏感性。消化内镜对消化系统肿瘤取样具有独特的优势,但目前国内尚无关于经内镜消化系统恶性肿瘤组织取样及后续相关类器官培养的共识。2024年,中华医学会消化病学分会医工交叉协作组组织全国领域内权威专家讨论,结合国内外循证与生物实验证据,形成了内镜取样与类器官培养专家共识,以期规范各医疗机构与类器官培养平台操作。本共识包括内镜取样适应证与伦理、内镜取样、样本存储与运输和类器官培养等4个部分,共15条陈述。

Gastrointestinal cancers are among the top-ranking malignancies globally,with both high incidence and mortalities.Some advanced tumor need to receive further chemotherapy,radiotherapy,targeted therapy or immunotherapy.The sensitivity of tumor cells to treatment is the key factor that determines patients'outcomes.Tumor organoids could be used to evaluate therapeutic sensitivity,because its genetic characteristics and biological behaviors are highly consistent with the original tumors.Digestive endoscopy has unique advantages in digestive malignant tumor biopsy.However,there was no consensus concerning endoscopic tissue biopsy and corresponding tumor organoid culture methods of digestive malignant tumor at present in China.Therefore,Medical-Engineering Collaborative Group,Gastroenterology Branch of Chinese Medical Association organized authoritative experts in this field to formulate this expert consensus regarding endoscopic biopsy and organoids culture methods combining evidence-based and bio-experimental evidence at home and abroad so as to standardize operational protocol in medical institutes and platforms of organoid culture.This consensus is composed of four categories including indication and morality,endoscopic biopsy,sample storage and transportation,and organoid culture with 15 statements.